Drug
Tisotumab Vedotin
Tisotumab Vedotin: highest development phase Phase 3, developed by Pfizer, Seagen, Zai Lab. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Pfizer, Seagen, Zai Lab
Trials
| Drug | Phase | Indication |
|---|---|---|
| tisotumab vedotin NCT04697628 | Phase 3 | Cervical Cancer |
| tisotumab vedotin NCT03657043 | Phase 2 | Ovarian Cancer |
| tisotumab vedotin NCT03438396 | Phase 2 | Cervical Cancer |
| tisotumab vedotin NCT03485209 | Phase 2 | Colorectal Neoplasms |
| Tisotumab vedotin (HuMax-TF-ADC) NCT02552121 | Phase 1/2 | Ovary Cancer |
| Tisotumab Vedotin NCT05866354 | Phase 1 | Solid Malignancies |
Latest
No recent events.
Follow Tisotumab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.